1. Academic Validation
  2. Photodynamic Therapy Initiated Ferrotherapy of Self-Delivery Nanomedicine to Amplify Lipid Peroxidation via GPX4 Inactivation

Photodynamic Therapy Initiated Ferrotherapy of Self-Delivery Nanomedicine to Amplify Lipid Peroxidation via GPX4 Inactivation

  • ACS Appl Mater Interfaces. 2022 Nov 18. doi: 10.1021/acsami.2c15495.
Lin-Ping Zhao 1 2 Shao-Yi Chen 1 Rong-Rong Zheng 1 Xiao-Na Rao 1 Ren-Jiang Kong 3 Chu-Yu Huang 1 Yi-Bin Liu 4 Youzhi Tang 4 Hong Cheng 3 Shi-Ying Li 1
Affiliations

Affiliations

  • 1 Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
  • 2 Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China.
  • 3 Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China.
  • 4 Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
Abstract

Lipid peroxide (LPO) is the hallmark of Ferroptosis, which is a promising antitumor modality for its unique advantages. However, a cellular defense system would weaken the antitumor efficacy of ferrotherapy. Herein, a GPX4 inhibitor of ML162 and a photosensitizer of chlorine e6 (Ce6) are used to prepare the self-delivery nanomedicine (C-ML162) through hydrophobic and electrostatic interactions to enhance Ferroptosis by photodynamic therapy (PDT). Specifically, carrier-free C-ML162 improves the solubility, stability, and cellular uptake of antitumor agents. Upon LIGHT irradiation, the internalized C-ML162 generates large amounts of Reactive Oxygen Species (ROS) to oxidize cellular unsaturated lipid into LPO. More importantly, C-ML162 can directly inactivate GPX4 to enhance the accumulation of toxic LPO, inducing ferroptotic cell death. Additionally, C-ML162 is capable of accumulating at a tumor site for effective treatment. This self-delivery system to amplify lipid peroxidation via GPX4 inactivation for PDT initiated ferrotherapy might provide an appealing strategy against malignancies.

Keywords

GPX4 inactivation; carrier free; ferrotherapy; lipid peroxides; photodynamic therapy.

Figures
Products
Inhibitors & Agonists
Other Products